Previous close | 2.220 |
Open | 2.210 |
Bid | 2.070 x 0 |
Ask | 2.080 x 0 |
Day's range | 2.060 - 2.210 |
52-week range | 1.620 - 6.220 |
Volume | |
Avg. volume | 3,519,730 |
Market cap | 2.657B |
Beta (5Y monthly) | 0.14 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.690 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.00 |
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced a strategic partnership and exclusive licensing agreement with Shenyang Sunshine Pharmaceutical Co., Ltd., a subsidiary of 3SBio Inc. ("3SBio", HKEX: 1530) for an anti-PD-1 antibody nofazinlimab in mainland China.
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the National Medical Products Administration (NMPA) of China has approved the anti-PD-L1 antibody sugemalimab (Cejemly®) for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL). Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal an